Transform treatment by harnessing the power of T cells to create a new generation of targeted cancer immunotherapies and infectious disease vaccines.
About PDS Biotech
PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body’s own immune system to induce a powerful T cell response, most have been unsuccessful in inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack. Scientists at PDS Biotech designed proprietary cationic, lipid-based nanoparticle platform technologies to overcome these limitations.
When paired with proprietary tumor-associated proteins called antigens, Versamune® has been shown to promote the induction of the right type and quantity of potent tumor-infiltrating killer and helper T cells, that specifically recognize the tumor antigen. PDS0301, our novel tumor-targeting IL-12 immunotherapy, when used with Versamune® overcomes tumor-induced suppression of the immune system. The proprietary combination also promotes enhanced infiltration and expansion of the T cells within the tumor leading to more effective immunotherapy. Our Infectimune® platform is being used in the development of novel T cell and antibody inducing preventive vaccines.
PDS Biotech is committed to developing novel immunotherapies based on our T cell activating platforms to save and improve the lives of patients worldwide:
- Versamune® based immunotherapies to provide a targeted T cell attack against tumor-associated proteins called antigens
- Versamune® based immunotherapy plus PDS0301, our novel tumor-targeting IL-12 immunotherapy, promotes enhanced infiltration and expansion of the T cells within the tumor to treat recurrent/metastatic cancers with poor survival prognosis
- Infectimune® based vaccines to provide robust and durable protection against selected deadly infectious diseases